Monoclonal antibody MUC 2-63 recognses neuroenic tumours and has been used successfilly for radiimaging human malignant ghomas. We now show that the MUC 2-63 antigen has the same tissue distibution and molecular weght rae as the CD44 antigen and confirm the identity of these two molecule in bcking studies using MUC 2-63 and the CD44 anti-framework antibody FIO44-2. Thus not only MUC 2-63 but also other anti-CD44 monodcnal antibodies should prove useful in imaging and, perhaps, therapy of brain tumours.
The CD44 molecule was orginally defined by the monoclonal antibody FIO 442 and found predominantly on lymphohaemopoietic tissues and brain (Dalhau et al., 1980 , Stoll et al., 1989 . In man the CD44 antigen is expressed on T and B lymphocytes, granulocytes, monocytes/macrophages and the majority of erythrocytes (reviwed in Haynes et al., 1989; Stamenkovic et al., 1989) . It is acquired by medullary thymocytes during T-cell maturation in the thymus and is up-regulated on memory T cells (Dalchau et al., 1980; Haynes et al., 1983; Sanders et al., 1988) . CD44 is also present at low levels on normal epithelium, but is highly expressed on carcnomas, including those of the colon (Daar & Fabre, 1983; Stamenovic et al., 1989) . In human brain the molecule has a molkeular weight of 90kDa, while a lymphoid form of 80-90kDa (CD44H) and an epitheial form of 160 kDa (CD44E) have been described (McKenzie et al., 1982; Stamenkovic et al., 1989 Stamenkovic et al., , 1991 Brown et al., 1991) . The diferences between these and other isoforms, ranging in molcular weight from 85 to 250 kDa, lie in the membraneproximal region and result from alternative splicing of at least ten different exons and from post-translational modifications (Brown et al., 1991; Jackson et al., 1992; Screaton et al., 1992; Tolg et al., 1993) .
Many functions involving cell-cell and cell-extracellular matrix interactions have been attributed to CD44, and are likely to be mediated by different isoforms (Belitsos et al., 1990; Staovic et al., 1991; Jalkanen & Jalkanen, 1992) . Such interactions play a role in cell development, activation and migration (Berg et al., 1989; Miyake et al., 1990; Ritter & Crispe, 1992; Haegel et al., 1994) . Differential expression of CD44 variants has been observed on some epithelial, neuronal and lymphoid tumour cells compared with their normal counterparts, and between metastatic and non-metastatic tumours; this may prove usefu in diagnois and disease evaluation (Matsumura & Tarin, 1992; Koopman et al., 1993; Salmi et al., 1993) . Moreover, there is compelling evidence in support of a role for CD44 in tumorigenesis in the rat, in which expson of the p-meta-I splice variant confers metastatic potential on tumour cells that were previously non-metastatic (Glinthert et al., 1991 (Stavrou et al., 1987) . Radiolabelled MUC 2-63 was subsequently successfully used in vivo for ig of glioma (Bergh et al., 1990; Stavrou et al., 1991) . Although preliminary biochemical analysis of the MUC 2-63 antigen yielded moleular weights from 80 to 190 kDa, the exact nature of the molecule detected by MUC 2-63 was not known (Stavrou et al., 1990) .
We (Stavrou et al., 1987) . Two independent preparations were produced from separate cell stocks and used as supernatant (London) and purified IgG (Hamburg); these gave identical results in all experimental systems. Antibodies for FACS analysis were: anti-CD3 (1:10; Dakopatts, Denmark), anti-CD22 (1:10; Dakopatts), anti-macrophage (1:10; Dakopatts) and fluorescein-conjugated anti-CD4 (CD44-FITC, 1:5; Serotec, UK). An irrelevant isotype-matched antibody was used as negative control in immunostaining. MR6, an IgGI antibody that detects a 200 kDa molecule on the surface of most thymocytes, tonsillar lymphocytes and PBMCs, was used as the control for the blocking studies (Larche et al., 1988 Laemmli, 1970) and analysed by Western blotting using MUC 2-63, followed by RAM-PX and the substrate diaminobenzidine (DAB) (Towbin et al., 1979; Larche et al., 1988) .
Resuts
Immunohistochemistry On thymus sections MUC 2-63 showed strong staining of all medullary thymocytes and small scattered groups of cortical thymocytes (Figure lb) . It also labelled blood vessels and Hassall's corpuscles, but no other thymic epithelium. On tonsil sections MUC 2-63 strongly stained B-and T-cell areas, blood vessels, epithelial cells and follicular dendritic cells; however, the germinal centre region stained less intensely than the outer areas of the follicle ( Figure Id) .
In all seven normal and adenoma colon samples tested MUC 2-63 gave moderate to strong staining of both epithelium and lamina propria. Seven of the nine colonic carcinomas were also moderately to strongly MUC 2-63 positive, while in two the epithelium was only weakly positive (Table I) . Similarly, all normal skin and naevi samples and 11 of 14 basal cell carcinomas (BCCs) showed strong staining with MUC 2-63, the remaining three being only weakly positive (Table I, Figure If) . In eight of the BCCs only a proportion of the tumour cells were positive (-50%).
The staining patterns seen with anti-CD44-FITC were indistinguishable from those given by MUC 2-63 (Figures la, c and e).
Western blotting analysis of the MUC 2-63 antigen Thymus lysates gave a single band at -90 kDa. Normal colon gave a major band at 9-% kDa and a minor band at -137 kDa which was not visible on all blots, probably because of differences in the amount of protein loaded (Figure 2) . Similarly, colon adenoma showed a major (-180 kDa) and a minor (-90 kDa) band, while colonic carcinoma gave bands at -150 kDa (major component) and -90 kDa (minor component). Since the -90 kDa bands on both adenoma and carcinoma were weak they could represent breakdown product of the larger, major, band; alternatively, they could represent infiltrating leucocytes. BCC also gave two bands, at -96 kDA and -143 kDa (not shown). (Table II) . An isotype-matched control monoclonal antibody, MR6, which bound to > 50% of the cells in each of the preparations used, had no effect on CD44-FITC binding. Similar antibody blocking data were obtained with tumour tissue using MUC 2-63 followed by CD44-FITC on frozen sections of basal cell carcinoma ( Figure Ig and h ).
Diso
Monoclonal antibody MUC 2-63 was one of several reagents raised for typing brain tumours (Stavrou et al., 1987 onginal study it was shown to react with gliomas, neuroblastomas and melanomas. but not with any of the non-neurogenic tumours tested. MUC 2-63 was subsequently successfully used in in vivo radioimaging (Bergh et al., 1990) . We included MUC 2-63 in a recent study of epithelial tumours of skin and colon as part of an ongoing analysis of epithelial antigen expression dunng tumorigenesis (Mat et al., 1990 (Mat et al., . 1993 . All antibodies in this study were tested on sections of human thymus as a positive control for the immunoperoxidase staining. Surprisingly. MUC 2-63 strongly labelled small groups of cortical and all medullary thymocytes. suggesting that the MUC 2-63 antigen is acquired with T-lymphocyte maturation. This was further analysed in tonsil and PBMC preparations. in which MUC 2-63 was found to label mature T and B lymphocytes and macrophages. Analysis of tumour tissue revealed MUC 2-63 antigen on epithelium. connective tissue and infiltrating leucocytes in all samples studied, although there was some variation in the intensity and in the proportion of epithelial cells within a tumour that were labelled. The molecular weight of the molecule recognised by MUC 2-63 in these tissues was analysed by Western blotting on thymus. colon and skin lysates. These experiments showed that the antigen is expressed in two main molecular weight forms of -90 kDa and -150 kDa.
These molecular weight data were strongly reminiscent of data previously published for CD44, with a lymphoid form of 80-90 kDa and an epithelial form of 160 kDa resulting from alternative exon splicing (Stamenkovic et al.. 1989 : Jackson et al., 1992 Tolg et al., 1993) . In addition to these two cell-specific isoforms, several minor forms ranging in molecular weight from 50 kDa to 200 kDa and variably present on different cell types have been described (Stamenkovic et al., 1989; Guinthert et al., 1991; Jackson et al., 1992) . We also saw additional minor bands on some Western blots.
Moreover, cell distribution data for MUC 2-63 also matched that reported for CD44. Thus both antigens are acquired during thymocyte maturation and are present on mature T and B lymphocytes, monocytes,macrophages, connective tissue and colorectal tumours (Dalchau et al., 1980; McKenzie et al., 1982; Haynes et al., 1983; Daar & Fabre, 1983; Stoll et al.. 1989) . Our previous failure to detect MUC 2-63 on epithelial tumours resulted from the use of cell lines rather than fresh tumour samples as used in the current study (Stavrou et al., 1987) .
Our data therefore strongly suggested that MUC 2-63 detects an epitope present on all CD44 molecules. Blocking experiments using a well-characterised anti-'framework' anti-CD44 monoclonal antibody, F10-44-2, confirmed this specificity. The expression of MUC 2-63 on human malignant gliomas and neuroblastomas has important implications. Firstly, and as previously demonstrated, the molecule provides an effective target for in vivo imaging of brain tumours and, if administered intratumorally or intrathecally, may provide effective immunotherapy for these tumours (Bergh et al.. 1991) . Secondly, the MUC 2-63/CD44 molecule may be involved in tumour development, possibly controlling cell growth or migration via interactions with the extracellular matnrx (Stamenkovic et al., 1991; Jalkenen & Jalkenen, 1992 : Knudson et al.. 1993 ). Thus MUC 2-63 and other anti-CD44 monoclonal antibodies should also provide useful tools with which to study tumonrgenesis in the brain.
